IRCT20210519051345N60尚未招募Unknown
In vivo bioequivalence study of Anagrelide 0.5 mg capsule manufactured by Pars Darou Co. compared with innovator product
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 59 years（—）
- 性别
- All
入选标准
- •General Health (in terms of Liver, Heart and Kidney)
- •Age between 18-59 years
排除标准
- •History of cardiovascular disease, liver and kidney disease
- •Alcohol and drug addiction
- •History of drug allergy
研究者
相似试验
招募中
不适用
Investigating the in vivo bioequivalence of Anagrelide 0.5 mg capsuleIn the present study, the products will be administered to healthy volunteers..IRCT20210519051345N27Tabriz University of Medical Sciences24
招募中
Unknown
Anagrelide capsule BioequivalenceIRCT20130313012810N30Modava Pharmaceutical Company24
招募中
不适用
In-vivo Bioequivalence study of Clopidegrel tablet with brand drugs (PLAVIX SANOFI, USA)IRCT20200105046010N35SanaMed Co.24
已完成
1 期
Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mgHealthyNCT00648024Mylan Pharmaceuticals Inc47
已完成
不适用
Bioequivalence study of Agomelatine 25 mg in healthy volunteer under fasting conditioBioequivalence study of agomelatine 25 mgTCTR20200903006nison Laboratories Co., Ltd.36